Skip to Main Content
Skip Nav Destination

Since the mid-1990s, pharmaceutical R&D productivity has experienced what at best can be described as a downturn. From 1998 to 2008 the number of new molecular entities has been in general decline whereas attrition rates, development times and expenditure have all increased

This content is only available via PDF.
You do not currently have access to this chapter, but see below options to check access via your institution or sign in to purchase.
Don't already have an account? Register
Close Modal

or Create an Account

Close Modal
Close Modal